Evidence map›Paper›PMID 33046726›Full record

ArticleScientific data2020

Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAF

Lorey K Smith, Tiffany Parmenter, Cathryn M Gould, Piyush B Madhamshettiwar, Karen E Sheppard, Kaylene J Simpson, Grant A McArthur

Open access · goldAbstract readDataset
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific data, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lorey K Smith *Cancer Research Division, Peter MacCallum Cancer Centre, Parkville, Australia. lorey.smith@petermac.org.
Tiffany Parmenter *Cancer Research Division, Peter MacCallum Cancer Centre, Parkville, Australia.
Cathryn M GouldVictorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Parkville, Australia.
Piyush B MadhamshettiwarVictorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Parkville, Australia.
Karen E SheppardCancer Research Division, Peter MacCallum Cancer Centre, Parkville, Australia.ORCID http://orcid.org/0000-0002-2798-4703
Kaylene J Simpson *Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Parkville, Australia.
Grant A McArthur *Cancer Research Division, Peter MacCallum Cancer Centre, Parkville, Australia. grant.mcarthur@petermac.org.
Peter MacCallum Cancer Centre · AUThe University of Melbourne · AU

Funding

Department of Health | National Health and Medical Research Council (NHMRC) 1106576
6 · The paper itself

Abstract

Identification of mechanisms underlying sensitivity and response to targeted therapies, such as the BRAF inhibitor vemurafenib, is critical in order to improve efficacy of these therapies in the clinic and delay onset of resistance. Glycolysis has emerged as a key feature of the BRAF inhibitor response in melanoma cells, and importantly, the metabolic response to vemurafenib in melanoma patients can predict patient outcome. Here, we present a multiparameter genome-wide siRNA screening dataset of genes that when depleted improve the viability and glycolytic response to vemurafenib in BRAF

Indexed as

RNA InterferenceAntineoplastic AgentsCell Line, TumorGlycolysisHumansMelanomaProto-Oncogene Proteins B-rafVemurafenibAntineoplastic AgentsProto-Oncogene Proteins B-rafVemurafenib

Identifiers

PMID33046726
PMCPMC7550327
OpenAlexW3092419705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.